• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

手机动态码快速登录

手机号快速注册登录

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
194454 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  + H& }$ q( K! |) f
$ b4 h! D) q1 R1 w0 f8 i- L9 a

/ l6 k' j: u* QSub-category:
  ~* z! R" k+ m% O+ _4 L/ _) OMolecular Targets ; C7 Y7 u; |+ I- Q1 w

  n8 \. ]  g+ `+ G3 O% E9 q& q2 |2 w3 m* u: J3 P6 u
Category:# y/ [6 l" Y5 b4 Y
Tumor Biology   N4 g+ [! a6 z0 h( h8 p" ?" H5 ^% [
' ]+ M! ?" X6 z0 [2 \) ?1 ]) a

# o8 k7 d5 Y  G0 `Meeting:
' C& l4 C" Y' t2011 ASCO Annual Meeting
! ~8 }( |. r& N3 x: S2 @4 z* r+ O+ A
- v5 ^" o0 g6 s! Q* X
Session Type and Session Title:
* u2 U) B6 Z$ tPoster Discussion Session, Tumor Biology
& ]5 o. c/ t  G2 Z7 S3 k0 e- I% P0 d7 \" e* f1 }

( j8 `' j# Z# uAbstract No:! [, }7 u) I2 J) W
10517 ( V6 G) p% o3 H! }* u
: g9 G( W4 z8 X2 H) u( L, x" Z# j
0 p4 [/ j( i( Z& D" {
Citation:0 W! N, ^: U3 d
J Clin Oncol 29: 2011 (suppl; abstr 10517) $ R( F# z& I7 ]5 A5 {+ _% c

& h1 ^1 N9 {5 D* C: H2 ]# S5 Q' I; ?" @
Author(s):/ Y( L' \& J" C: ^5 Y, \
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- H4 j1 B1 F# ]" J
5 T+ u- q# o4 H4 ?5 A9 L& U- y% {6 S2 [# _% s+ l- P% d) ?* q
6 u. _* i2 u9 M# z
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.1 d. u4 u% _" E1 G5 i- {
9 x: @2 `3 y5 X4 }5 ~" i: c2 w
Abstract Disclosures
/ c! @0 f7 v: D
% {3 D- I% B7 |: T7 H- P& qAbstract:# z% V5 f9 x8 B9 \

! T# C# f' l; `' `+ f' R
! G# X, m* M! qBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 \3 C3 Y+ l& o% n. i9 `& H, h/ o1 }0 r2 z

0 @9 e! J( Q' I  A
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
  S8 B; C: ?- p3 D没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
8 j6 {$ B% w- g2 ?# Z
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
1 U) _, g3 Y- |6 l易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
* t: R* b& h8 V3 B5 K0 j2 _ALK一个指标医院要900多 ...

7 p  e: B, ~  z( _9 j" @/ K4 z* P8 w平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?, L1 H( M+ G5 H7 A
: M! M! x" O+ `" X& |& e3 ~* r- S
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册 手机动态码快速登录

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表